Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
← SearchNorthwestern2023Affirmative
Opening Word document…

High prices are used for increasing stock value, not innovation

William Lazonick 17, Professor of Economics at the University of Massachusetts Lowell, Visiting Professor at the University of Ljubljana, Matt Hopkins, Ken Jacobson, Mustafa Erdem Sakinç Assistant Professor of Economics at University of Paris, Öner Tulum, PhD Candidate at the University of Ljubljana, 7-13-2017, “US Pharma’s Financialized Business Model” Institute for New Economic Thinking, Working Paper Number 60, https://www.ineteconomics.org/uploads/papers/WP_60-Lazonick-et-al-US-Pharma-Business-Model.pdf, Date Accessed: 8-1

It is a compelling argument—until one looks at how major US pharmaceutical companies actually use the profits that high drug prices generate. In the name of “maximizing shareholder value” (MSV), pharmaceutical companies allocate profits generated by high drug prices to massive repurchases, or buybacks, of their own corporate stock for the sole purpose of giving manipulative boosts to their stock prices. Incentivizing these buybacks is stock-based compensation that rewards senior executives for increases in their companies’ stock prices (Lazonick 2014b; Lazonick 2014c; Lazonick 2015b; Hopkins and Lazonick 2016).

Like no other sector, the pharmaceutical industry puts a spotlight on how the political economy of science is a matter of life and death. In this paper, we invoke “the theory of innovative enterprise” to explain how and why high drug prices restrict access to medicines and undermine medical innovation. An innovative enterprise seeks to develop a high-quality product that it can sell to the largest possible market at the most affordable price (Lazonick 2015c). In sharp contrast, the MSV-obsessed companies that dominate the US drug industry have become monopolies that restrict output and raise price. This paper exposes the financialized business model that dominates the US pharmaceutical drug industry. From the perspective of the theory of innovative enterprise, we call for a number of policy measures to transform the industry from one that has become the source of concentrations of obscene wealth to one that can enable the world’s population to improve their health.

Sign in to recut, update, or save this card.